A benefit/risk assessment of existing therapeutic alternatives for the treatment of painful inflammatory conditions

被引:1
|
作者
Ehrlich, GE [1 ]
机构
[1] Univ Penn, Philadelphia, PA 19104 USA
[2] NYU, Philadelphia, PA USA
关键词
non-steroidal anti-inflammatory drugs; benefit/risk; adverse events; COX-2; inhibitors; nimesulide;
D O I
10.1111/j.1742-1241.2004.020_d.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pain remains the leading reason for which patients consult their doctors. Pain also motivates over-the-counter sales of analgesic medicines, to be taken orally or even transcutaneously. Prescription medicines usually follow attempts at self-medication that fail to achieve the desired results. Acute pain usually subsides spontaneously but medicines are needed until that occurs; in arthritic conditions sigma especially osteoarthritis sigma anti-inflammatory drugs work best in short-term administration for flares that aggravate chronic but tolerable pain. In cases of chronic pain that exceeds the level of easy tolerance, anti-inflammatory drugs can reduce the pain to tolerable levels more effectively than simple analgesics and narcotic combinations. The non-steroidal anti-inflammatory drugs (NSAIDs) are among the most useful medicines providing an array of drugs that differ chiefly in time of onset of action, duration of action and persistence in the blood. The benefit they provide is pain amelioration; none is curative. The risks are well known and do not differ greatly among the drugs; unwanted gastrointestinal (GI) effects are the most common, but the skin, kidneys, liver and blood forming organs may also be affected. As the benefits are similar, when balancing risk and benefit it is important to: consider the cause and expected duration of pain, balance the risks (GI unwanted effects far outnumber others), assess the severity and likelihood of specific reactions, and consider the costs sigma not only of the medicines themselves but also those of treating untoward reactions. Thus NSAIDs number among the most successful therapeutic options of modem medicine and, as pain will continue to require intervention, will likely continue sigma at least as ancillary medications sigma even as more definitive treatments are developed. In addition, the target population, its characteristics and the duration and acceptance of the intervention need to be considered.
引用
收藏
页码:20 / 26
页数:7
相关论文
共 50 条
  • [31] A risk-benefit assessment of sildenafil in the treatment of erectile dysfunction
    Vitezic, D
    DRUG SAFETY, 2001, 24 (04) : 255 - 265
  • [32] A Risk-Benefit Assessment of Sildenafil in the Treatment of Erectile Dysfunction
    Dinko Vitezic
    Drug Safety, 2001, 24 : 255 - 265
  • [33] A Benefit-Risk Assessment of Medical Treatment for Uterine Leiomyomas
    Vincenzo De Leo
    Giuseppe Morgante
    Antonio La Marca
    Maria Concetta Musacchio
    Massimo Sorace
    Chiara Cavicchioli
    Felice Petraglia
    Drug Safety, 2002, 25 : 759 - 779
  • [34] Benefit-Risk Assessment of Dronedarone in the Treatment of Atrial Fibrillation
    Adlan, Ahmed M. A.
    Lip, Gregory Y. H.
    DRUG SAFETY, 2013, 36 (02) : 93 - 110
  • [35] Risk-benefit assessment of methotrexate in the treatment of severe psoriasis
    Kuijpers A.L.A.
    Van De Kerkhof P.C.M.
    American Journal of Clinical Dermatology, 2000, 1 (1) : 27 - 39
  • [36] A RISK-BENEFIT ASSESSMENT OF CISAPRIDE IN THE TREATMENT OF GASTROINTESTINAL DISORDERS
    TACK, J
    COREMANS, G
    JANSSENS, J
    DRUG SAFETY, 1995, 12 (06) : 384 - 392
  • [37] A Benefit-Risk Assessment of Dapoxetine in the Treatment of Premature Ejaculation
    Kate Hutchinson
    Kelly Cruickshank
    Kevan Wylie
    Drug Safety, 2012, 35 : 359 - 372
  • [38] RISK-BENEFIT ASSESSMENT OF OMEPRAZOLE IN THE TREATMENT OF GASTROINTESTINAL DISORDERS
    CREUTZFELDT, W
    DRUG SAFETY, 1994, 10 (01) : 66 - 82
  • [39] Benefit-Risk Assessment of Infliximab in the Treatment of Rheumatoid Arthritis
    Ted R. Mikuls
    Larry W. Moreland
    Drug Safety, 2003, 26 : 23 - 32
  • [40] Benefit-risk assessment of infliximab in the treatment of rheumatoid arthritis
    Mikuls, TR
    Moreland, LW
    DRUG SAFETY, 2003, 26 (01) : 23 - 32